AtriCure (ATRC) Scheduled to Post Quarterly Earnings on Tuesday

AtriCure (NASDAQ:ATRC) will be announcing its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. AtriCure has set its FY 2024 guidance at -0.820–0.740 EPS.Investors interested in listening to the company’s conference call can do so using this link.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). The firm had revenue of $116.27 million during the quarter, compared to analysts’ expectations of $116.24 million. AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. The business’s revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AtriCure Stock Down 2.6 %

Shares of NASDAQ ATRC opened at $27.93 on Monday. The stock has a market cap of $1.33 billion, a PE ratio of -34.91 and a beta of 1.44. The company has a quick ratio of 2.93, a current ratio of 4.13 and a debt-to-equity ratio of 0.16. AtriCure has a 52-week low of $18.94 and a 52-week high of $43.00. The business has a 50-day moving average price of $27.25 and a 200 day moving average price of $24.25.

Insiders Place Their Bets

In other news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $24.07, for a total value of $84,245.00. Following the completion of the transaction, the director now owns 8,970 shares in the company, valued at $215,907.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. JPMorgan Chase & Co. decreased their price objective on AtriCure from $34.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Stifel Nicolaus decreased their price objective on AtriCure from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. BTIG Research decreased their price objective on AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Finally, Needham & Company LLC decreased their price objective on AtriCure from $40.00 to $34.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.